PMID- 22161775
OWN - NLM
STAT- MEDLINE
DCOM- 20120430
LR  - 20181201
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 118
IP  - 5
DP  - 2012 Mar 1
TI  - Epidermal growth factor receptor protein expression and genomic alterations in 
      renal cell carcinoma.
PG  - 1268-75
LID - 10.1002/cncr.26436 [doi]
AB  - BACKGROUND: Epidermal growth factor receptor (EGFR) is involved in the 
      progression of many cancer types and represents an important therapeutic target. 
      METHODS: To determine the role of EGFR in renal cell carcinoma (RCC), the authors 
      analyzed 1088 tumors in a tissue microarray format by using immunohistochemistry 
      and fluorescence in situ hybridization (FISH). A subset of 63 cancers was 
      sequenced for EGFR exon 18 through 21 mutations. RESULTS: EGFR expression was 
      observed in 83.8% of clear cell carcinomas, in 68.2% of papillary carcinomas, in 
      75% of chromophobe carcinomas, and in 50% of oncocytomas. Within clear cell 
      carcinomas, the expression level of EGFR was associated with high tumor grade (P 
      < .0001), advanced pathologic tumor classification (P < .0001), and, to a lesser 
      extent, lymph node status (P = .0326). FISH analysis revealed increased EGFR copy 
      numbers (high polysomy) in 5.5% of tumors and amplification in 0.1% of tumors. 
      EGFR copy number increases were associated with EGFR protein expression (P = 
      .0015). Within clear cell carcinomas, EGFR copy number increases were associated 
      with high tumor grade (P < .0001), advanced pathologic tumor classification (P = 
      .0472), and lymph node status (P = .0065). No exon 18 through 21 mutations were 
      identified in 63 sequenced tumors. CONCLUSIONS: The authors concluded that 
      increased EGFR expression occurs in a fraction of patients who have RCC with an 
      unfavorable histologic phenotype. EGFR copy number gain represents 1 possible 
      cause for EGFR overexpression; however, many over expressing tumors have a normal 
      genotype. High polysomy (which is suggested to be predictive of a response to 
      tyrosine kinase inhibitors) occurs in 5.6% of RCCs. Thus, the potential utility 
      of anti-EGFR medications may be worth further investigation in a small but 
      significant subset of patients with RCC.
FAU - Minner, Sarah
AU  - Minner S
AD  - Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, 
      Germany. s.minner@uke.uni-hamburg.de
FAU - Rump, Dorothea
AU  - Rump D
FAU - Tennstedt, Pierre
AU  - Tennstedt P
FAU - Simon, Ronald
AU  - Simon R
FAU - Burandt, Eike
AU  - Burandt E
FAU - Terracciano, Luigi
AU  - Terracciano L
FAU - Moch, Holger
AU  - Moch H
FAU - Wilczak, Waldemar
AU  - Wilczak W
FAU - Bokemeyer, Carsten
AU  - Bokemeyer C
FAU - Fisch, Margit
AU  - Fisch M
FAU - Sauter, Guido
AU  - Sauter G
FAU - Eichelberg, Christian
AU  - Eichelberg C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Carcinoma, Renal Cell/epidemiology/*genetics/*metabolism/pathology
MH  - Chromosome Aberrations/statistics & numerical data
MH  - DNA Mutational Analysis
MH  - ErbB Receptors/*genetics/*metabolism
MH  - Gene Dosage
MH  - Gene Expression Regulation, Neoplastic
MH  - Genome, Human
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kidney Neoplasms/epidemiology/*genetics/*metabolism/pathology
MH  - Mutation/physiology
MH  - Neoplasm Staging
MH  - Tissue Array Analysis
EDAT- 2011/12/14 06:00
MHDA- 2012/05/01 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/05/01 06:00 [medline]
AID - 10.1002/cncr.26436 [doi]
PST - ppublish
SO  - Cancer. 2012 Mar 1;118(5):1268-75. doi: 10.1002/cncr.26436.